首页 | 官方网站   微博 | 高级检索  
     

肺积胶囊治疗晚期非小细胞肺癌的研究
引用本文:王笑民,郁仁存,孙书贤. 肺积胶囊治疗晚期非小细胞肺癌的研究[J]. 中国中医药信息杂志, 2003, 10(10): 18-20
作者姓名:王笑民  郁仁存  孙书贤
作者单位:1. 北京中医医院,北京,100010
2. 北京小汤山医院
基金项目:北京市科委资助项目(№.952871600)
摘    要:目的:观察中药肺积胶囊治疗晚期非小细胞肺癌(NSCLC)的近期疗效以及该制剂对实验肿瘤的抑瘤、抗转移作用。方法:临床观察112例晚期NSCLC患者,随机分为化疗组、肺积胶囊组及化疗加肺积胶囊组,比较三组病人的近期抗肿瘤疗效及症状变化。动物实验观察了肺积胶囊对Lewis肺癌及La795肺腺癌的抑瘤及抗转移效果,同时观察中药对实验动物免疫及血流变指标的影响。结果:与单纯化疗比较,中药组及中药加化疗组的症状积分显著降低(P<0.05)、生活质量评分明显提高(P<0.05);肺积胶囊及肺积胶囊加化疗组的PR+NC的比例分别为94.7%及88.5%,明显高于单纯化疗组(66.7%),P值分别小于0.01及0.05。实验研究证实,肺积胶囊对Lewis肺癌及La795肺腺癌瘤株有一定的抑制作用,对Lewis肺癌的自发性肺转移有抑制作用,对实验动物的免疫及血流变指标有改善作用。结论:肺积胶囊能改善晚期病人的生活质量、稳定肿瘤病灶,对实验肿瘤的生长及转移有一定的抑制作用,对荷瘤宿主免疫及血流变学的改善作用是其获得疗效的可能机理。

关 键 词:肺积胶囊 中药治疗 晚期非小细胞肺癌 近期疗效 肿瘤转移 化疗 生活质量
修稿时间:2002-12-10

Study on the Feiji Capsule in the Treatment of Advanced Non-small Cell Lung Cancer
Wang Xiaomin,Yu Rencun,Sun Shuxian. Study on the Feiji Capsule in the Treatment of Advanced Non-small Cell Lung Cancer[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2003, 10(10): 18-20
Authors:Wang Xiaomin  Yu Rencun  Sun Shuxian
Abstract:Objective: To evaluate the efficacy of Feiji capsule in the treatment of advanced Non-small cell lung cancer (NSCLC) and the tumor-inhibiting effect of Feiji capsule in the treatment of tumor-bearing mice. Methods: In the clinical observation, 112 advanced NSCLC patients were randomly allocated into three groups, they are chemotherapy, chemotherapy plus Feiji capsule and Feiji capsule alone. After treatment, the tumor response rate and patients' general condition were compared. In the experimental research, the tumor-inhibiting and anti-metastasis effects of Feiji capsule in the treatment of tumor-bearing mice were observed. Results: Compared with chemotherapy group, the cents of symptoms in Feiji capsule group and Feiji capsule plus chemotherapy group were lower significantly (P<0.05), while the cents of quality of life were higher obviously (P<0.05). The rate of PR+NC in Feiji capsule group and Feiji capsule plus chemotherapy group were 94.7% and 88.5% respectively, higher than that of chemotherapy group (P<0.01, 0.05). It has been demonstrated that Feiji capsule could inhibit the tumor group and metastasis in Lewis and La795 tumor-bearing mice, Feiji capsule could also improve the immune function and blood circulation in tumor-bearing mice. Conclusion: Feiji capsule could improve the quality of life and stable the tumor lesion in the treatment of advanced NSCLC. It could inhibit the growth and metastasis of experimental tumor and improve the immune function and blood circulation in tumor-bearing mice.
Keywords:Feiji capsule  advanced NSCLC  chemotherapy  experimental tumor  tumor-inhibiting  anti-metastasis
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号